Hainan Zhongwang Medical Technology Development Co., Ltd.

Primary objective: To evaluate the bioequivalence of the two preparations in Chinese healthy subjects in the fasting and postprandial states, using the ursodeoxycholic acid oral suspension (trade name: Ursofalk®, specification: 250mg:5ml) of Dr. Falk Pharma Gmbh as the reference preparation and the ursodeoxycholic acid oral suspension (specification: 250ml:12.5g) developed by Hainan Zhongwang Medical Technology Development Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in Chinese healthy subjects.

The main purpose of the study is to investigate the relative bioavailability of the single-dose oral (fasting/postprandial) test preparation metformin empagliflozin tablets (I) (specification: 500mg/5mg, produced by Hainan Huluwa Pharmaceutical Group Co., Ltd. commissioned by Hainan Zhongwang Medical Technology Development Co., Ltd.) and the reference preparation metformin empagliflozin tablets (I) (SYNJARDY®, specification: 500mg/5mg, Boehringer Ingelheim Pharmaceuticals Inc. licensed) in healthy Chinese subjects, analyze the pharmacokinetic parameters of the two preparations, evaluate the bioequivalence of the two preparations, and provide a reference for the application and clinical use of the drug. Secondary purpose of the study: To evaluate the safety of the test preparation and the reference preparation in Chinese healthy adult subjects after single oral administration on an empty stomach or after a meal